Commentary
Commentary
What the Biden-Harris COVID-19 Advisory Board is missing
Not having a single behavioral health provider on the advisory board will prove to be a mistake, said Dr. Ranna Parekh and Dr. Kali Cyrus.
Shrink Rap News
Can mental health teams de-escalate crises in NYC?
It will be important for the city to collect good outcome data to enable independent evaluation of the pilot project, said Dr. Dinah Miller.
Hard Talk
Excited delirium: Is it time to change the status quo?
The term comes at a cost, and there is concern of its disproportionate application to Black people, several psychiatrists contend.
Commentary
Sharing mental health notes with patients: Differentiating between access and accessibility
To retain their protected status, private psychotherapy notes must be kept separate and apart from the patient chart, say Lt. Col. Charles G. Kels...
Commentary
Tips for physicians, patients to make the most of the holidays amid COVID
Holidays are often about what we can do for others, but this year we may need to place self-care first, said Dr. Eva Ritvo.
Commentary
Practicing medicine without judgment
As physicians, we have a unique opportunity to see and hear people without judgment.
Commentary
Should our patients really go home for the holidays?
Risks to warn patients of include high-risk status, risk of SARS-CoV-2 transmission and how to mitigate it, and mode of transportation.
Commentary
How mental health care would look under a Trump vs. Biden administration
Three critical issues are key to understanding which candidate would best lead the mental health recovery, said Dr. Nina Vasan, Victor C. Agbafe,...
Commentary
Is ketamine living up to the promise for depression?
“In our view, [ketamine is] probably going to be as effective in bipolar disorder as it is in major depressive disorder, unipolar depression,”...
Commentary
Issues with the Maintenance of Certification program; Overcoming a ‘quadruple threat’
In Dr. Nasrallah’s editorial “Revamp the MOC,” he addresses the ABPN Maintenance of Certification program, which—in my opinion—is nothing more...
From the Editor
Unmet needs in the pharmacotherapy of psychiatric brain syndromes
The most glaring psychopharmacologic unmet need is that 80% of DSM disorders still do not have a single FDA-approved medication.